Propanc Biopharma, Inc. (NasdaqCM: PPCB)
Health Care · Biotechnology · AU
$1.16
+6.94% today · -98.7% 1Y
Propanc Biopharma, Inc. (NasdaqCM: PPCB) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.46M and employs 2 people.
Over the last twelve months the share price has lost 98.7%, trading between 0.95 and 100.00.
Tweenvest scores Propanc Biopharma, Inc. across four factors: quality 24/100. Its strongest factor is quality.
PPCB price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.46M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -32.41
- Dividend yield
- —
- Beta (5Y)
- 3.27
- 52-week high
- $100.00
- 52-week low
- $0.95
- Avg volume (3M)
- —
- Shares outstanding
- 2.28M
- Employees
- 2
- Next earnings
- —
About Propanc Biopharma, Inc.
Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on pancreatic, ovarian, and colorectal malignancies. The company's leading therapeutic candidate, PRP, is a unique formulation currently in the preclinical stage of development. This product is designed to enhance the effectiveness of multiple enzymes that work together to combat cancer. Propanc Biopharma is also engaged in a collaborative research effort with the University of Jaén, initiating the POP1 joint drug discovery program. Founded in 2007, the entity was originally known as Propanc Health Group Corporation before officially changing its name to Propanc Biopharma, Inc. in April 2017. The company's headquarters are located in Camberwell, Australia.
- ISIN
- US74346N8002
- Founded
- 2007
- Listed since
- Nov 12, 2012
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €864.20 | -4.19% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $138.89 | -4.26% |
Figures last refreshed Aug 18, 2026.